Walkty Andrew, Lagace-Wiens Philippe, Adam Heather, Baxter Melanie, Karlowsky James, Mulvey Michael R, McCracken Melissa, Zhanel George G
Department of Internal Medicine, Section of Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada; Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada.
Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada; Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada.
Diagn Microbiol Infect Dis. 2017 Jan;87(1):60-63. doi: 10.1016/j.diagmicrobio.2016.10.003. Epub 2016 Oct 7.
Pseudomonas aeruginosa is an important nosocomial pathogen. The purpose of this study was to evaluate the antimicrobial susceptibility profile of P. aeruginosa clinical isolates obtained from inpatients and outpatients at hospitals across Canada from January 2008 to December 2015 (CANWARD Study). Susceptibility testing was performed using broth microdilution, as described by the Clinical and Laboratory Standards Institute. In total, 2906 P. aeruginosa isolates were evaluated. The percentage of isolates susceptible to common antipseudomonal antimicrobials was: colistin 94.9%, amikacin 93.2%, piperacillin-tazobactam 84.3%, ceftazidime 83.1%, gentamicin 82.7%, meropenem 80.5%, ciprofloxacin 76.5%. In general, susceptibility to the antipseudomonal antimicrobials tested remained fairly stable or slightly improved (ciprofloxacin, gentamicin, colistin) over the 8year study period. Multidrug-resistant (MDR = non-susceptible to at least one antimicrobial from ≥3 classes) and extensively drug-resistant (XDR = non-susceptible to at least one antimicrobial from 5 classes) P. aeruginosa accounted for 14.5% and 2.6% of the isolates, respectively. Colistin remained active against 92.9% of MDR and 88.3% of XDR P. aeruginosa.
铜绿假单胞菌是一种重要的医院病原体。本研究的目的是评估2008年1月至2015年12月期间从加拿大各地医院的住院患者和门诊患者中分离出的铜绿假单胞菌临床菌株的抗菌药敏谱（CANWARD研究）。按照临床和实验室标准协会的描述，采用肉汤微量稀释法进行药敏试验。总共评估了2906株铜绿假单胞菌分离株。对常见抗假单胞菌抗菌药物敏感的分离株百分比为：黏菌素94.9%、阿米卡星93.2%、哌拉西林-他唑巴坦84.3%、头孢他啶83.1%、庆大霉素82.7%、美罗培南80.5%、环丙沙星76.5%。总体而言，在8年的研究期间，所测试的抗假单胞菌抗菌药物的敏感性保持相当稳定或略有提高（环丙沙星、庆大霉素、黏菌素）。多重耐药（MDR = 对至少3类中的至少一种抗菌药物不敏感）和广泛耐药（XDR = 对5类中的至少一种抗菌药物不敏感）的铜绿假单胞菌分别占分离株的14.5%和2.6%。黏菌素对92.9%的MDR铜绿假单胞菌和88.3%的XDR铜绿假单胞菌仍有活性。
